Substantial doubt about the company's ability to continue as a going concern.
“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Turn Therapeutics is developing topical immunomodulator GX-03 for moderate-to-severe eczema and onychomycosis, with an ongoing randomized trial and topline results expected mid-2026. The company also reported 100% recovery of a live VSV vaccine at 14 days ambient storage.
Turn Therapeutics Inc.'s proxy statement schedules a virtual annual meeting of stockholders on November 30, 2026 to elect two Class I directors and ratify WithumSmith+Brown, PC as auditor for fiscal year ending December 31, 2026, with 30,532,704 shares outstanding.
